This is a routine administrative filing with no trading signal. Monitor next quarterly earnings for fundamental performance; the dividend reinvestment pattern confirms the dividend was paid as scheduled.
Price Chart
Executive Summary
GSK filed a routine 6-K disclosing PDMR share transactions following the reinvestment of dividends paid on October 8, 2026. Multiple senior executives (CEO, CFO, CSO, and others) acquired small notional interests in ordinary shares and ADS through the company's Deferred Annual Bonus Plan and Performance Share Plan. These are automatic dividend reinvestment transactions, not discretionary open-market purchases, and carry no material signal for the stock.
Key Facts
- Dividend reinvestment transactions occurred on October 12, 2026, at £17.3550 per ordinary share and $46.5400 per ADS.
- CEO Luke Miels acquired 1,413 ordinary shares via the Deferred Annual Bonus Plan.
- CFO Julie Brown acquired 1,863 ordinary shares via the Deferred Annual Bonus Plan and an additional 2,409.639 ordinary shares via the Performance Share Plan (subject to a 2-year holding period).
- Chief Scientific Officer Tony Wood acquired 1,157 ordinary shares via the Deferred Annual Bonus Plan.
- President US Maya Martinez-Davis acquired 179.308 ADS via dividend reinvestment.
- Total aggregate notional interest acquired across all PDMRs was approximately 6,620 ordinary shares and 543 ADS.
- All transactions were automatic reinvestments of dividends paid on October 8, 2026, not discretionary purchases.
Financial Impact
Total value of PDMR acquisitions: approximately £114,900 in ordinary shares and $25,300 in ADS, immaterial relative to GSK's market cap.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-008950 |
| Document: 0001654954-26-008950-index-headers.html | 0001654954-26-008950 |
| Document: 0001654954-26-008950-index.html | 0001654954-26-008950 |
| Document: 0001654954-26-008950.txt | 0001654954-26-008950 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 28, 2026 today | 6-K | $49.07 | awaiting T+5 | awaiting T+5 | $48.74 (−0.67%) |
Oct 26, 2026 2d ago | 6-K | $51.10 | awaiting T+5 | awaiting T+5 | $48.74 (−4.62%) |
Oct 26, 2026 2d ago | 6-K | $51.10 | awaiting T+5 | awaiting T+5 | $48.74 (−4.62%) |
Oct 26, 2026 2d ago | 6-K | $51.10 | awaiting T+5 | awaiting T+5 | $48.74 (−4.62%) |
Oct 26, 2026 2d ago | 6-K | $51.10 | awaiting T+5 | awaiting T+5 | $48.74 (−4.62%) |
Oct 21, 2026 7d ago | 6-K | $50.02 $50.94 | ▲ +1.84% | ▲ +2.28% | $48.74 (−2.56%) |
Oct 19, 2026 9d ago | 6-K | $49.46 $51.10 | ▲ +3.32% | ▲ +3.46% | $48.74 (−1.46%) |
Oct 19, 2026 9d ago | 6-K | $49.46 $51.10 | ▲ +3.32% | ▲ +3.46% | $48.74 (−1.46%) |
Oct 15, 2026 13d ago | 6-K | $49.02 $51.21 | ▲ +4.47% | ▲ +5.48% | $48.74 (−0.57%) |
Oct 14, 2026 14d ago | 6-K | $47.87 $50.02 | ▲ +4.49% | ▲ +4.04% | $48.74 (+1.82%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers